---
title: "Supporting vaccine development"
featured: false
weight: 60
doi: https://doi.org/10.1016/S0140-6736(20)31604-4
---

[The Lancet, 15 August 2020]({{page.doi}})

At the start of the pandemic, ISARIC4C was able to provide convalescent
samples of PCR-positive hospitalised patients with COVID-19 to
characterise the immunological properties of COVID-19. This was
essential to the development of the viral vectored coronavirus vaccine
developed by the Oxford COVID Vaccine Trial Group.
